Ustekinumab Dose Based on BSA and Body Weight
CR108865
Phase 3 small_molecule completed
Quick answer
Ustekinumab Dose Based on BSA and Body Weight for Colitis, Ulcerative is a Phase 3 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Cilag International NV
- Indication
- Colitis, Ulcerative
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed